Core Viewpoint - Lepu Medical (300003.SZ) has reversed its declining performance, projecting significant growth in its 2025 annual results, with expected net profit ranging from 800 million to 1.2 billion yuan, representing a year-on-year increase of 223.97% to 385.95% [1][2] Financial Performance - For 2025, Lepu Medical anticipates both net profit and non-net profit to be between 800 million and 1.2 billion yuan, with median estimates indicating a growth of approximately 304.86% and 352.49% compared to the previous year [2] - The company experienced a decline in revenue and net profit in 2023 and 2024, with net profit dropping by 42.91% and 80.37% respectively [3][4] Business Segments - The core business of cardiovascular interventional devices has shown stable revenue growth, while the pharmaceutical segment has achieved double-digit growth due to the completion of inventory clearance in retail channels [5] - Strategic emerging sectors, including innovative drugs and dermatology, have contributed to the performance increase [5] Research and Development - Lepu Medical has consistently invested over 1 billion yuan annually in R&D, with total R&D expenditures from 2021 to 2024 being 11.12 billion, 12.84 billion, 12.42 billion, and 11.65 billion yuan respectively [7] - The company has developed several "firsts" in domestic medical technology, including bioabsorbable stents and dual-chamber cardiac pacemakers, establishing a strong competitive edge in the cardiovascular field [7] Financial Health - As of September 2025, the company's debt-to-asset ratio is approximately 30.71%, indicating a solid financial position [8] - Lepu Medical's operating cash flow has consistently shown net inflows, with a projected year-on-year increase of about 95% for 2025 [8]

Core Viewpoint - The Chinese medical industry has entered a new development stage influenced by multiple factors such as international expansion, centralized procurement mechanisms, and geopolitical dynamics. The focus has shifted from whether companies can go international to whether they possess the capability for long-term participation in global competition [2]. Group 1: Multi-Dimensional Collaborative Layout Capability - In the global high-end medical device sector, especially in complex disease and high-risk treatment scenarios, competitive advantage relies on systematic collaboration across different treatment stages and technological pathways rather than on single-point advantages [3]. - MicroPort Medical's business structure exemplifies strong representation in this dimension, covering multiple high-risk and high-tech core tracks, forming a business combination across cardiovascular, neurological, orthopedic, and surgical robotics fields [3]. Group 2: Clinical Closed-Loop Capability - The concept of "clinical closed-loop" in high-end medical devices refers to the ability to continuously and stably deliver medical solutions into real clinical systems, encompassing a complete chain from technological innovation to long-term follow-up [6]. - MicroPort Medical demonstrates distinctive features in this area, including a focus on Class III high-risk devices, a high density of "first/only" level technological innovations across multiple tracks, and a clinical technology foundation that integrates multiple pathways [7][8]. Group 3: Global Operational Capability - The true challenge of globalization lies not in the number of countries entered but in the ability to operate continuously under different regulatory systems, clinical environments, and commercial logics, forming long-term synergies across R&D, registration, supply chain, academia, and market [11]. - MicroPort Medical has established a multi-regional collaborative operational system, integrating domestic and overseas markets into a cohesive global framework, leveraging its product and clinical foundation in China to accelerate market entry for new technologies and products [12]. Group 4: Academic-Driven International Pathway - In mature markets like Europe, clinical and academic evidence is crucial for entering mainstream medical systems. MicroPort Medical has built academic recognition through high-quality clinical data and multi-center studies, maintaining close collaborations with key opinion leaders (KOLs) [16]. - The company's products have completed international multi-center clinical studies, establishing a strong academic influence and clinical trust in overseas markets [16][18]. Group 5: Industry Observation - As the industry evolves, global competition is increasingly focused on integrated capabilities encompassing technology R&D, clinical transformation, and data accumulation, raising higher demands for organizational systems and cross-field collaboration [21]. - MicroPort Medical's practices provide a valuable reference for how Chinese medical device companies can establish long-term competitiveness in the global high-end system [21].

Investment Rating - The report initiates coverage with an "Outperform" rating for the company [4] Core Insights - Lepu Medical, as a leading player in the cardiovascular sector, is experiencing stable growth in traditional business while exploring new growth avenues in aesthetic medicine and innovative drugs, which are expected to significantly enhance profits in the next 1-5 years and beyond [1][4] - The company has a diverse product matrix and is focusing on innovative drug development, particularly in the cardiovascular and metabolic disease sectors, with promising clinical trials underway [4][21] - The aesthetic medicine segment is rapidly expanding, with several key products recently approved, indicating a strong potential for market growth [4][24] Financial Summary - Total revenue is projected to decline from 79.8 billion in 2023 to 61.03 billion in 2024, followed by a gradual recovery to 87.67 billion by 2027, reflecting a CAGR of 12.8% from 2025 to 2027 [3][5] - Net profit is expected to drop significantly from 1.258 billion in 2023 to 247 million in 2024, before rebounding to 1.506 billion by 2027, indicating a strong recovery trajectory [3][5] - Earnings per share (EPS) is forecasted to increase from 0.57 in 2025 to 0.80 in 2027, reflecting the company's improving profitability [4][5] Business Segments Cardiovascular Sector - Lepu Medical is a comprehensive solution provider for cardiovascular diseases, with a strong focus on innovation and a robust product pipeline, including several "firsts" in the domestic market [9][17] - The company has seen a stable return to profitability in its traditional business, with a slight decline in revenue in the first half of 2025, indicating resilience in a competitive market [4][9] Innovative Drug Development - The company is strategically positioned in the innovative drug sector through its subsidiary, Minwei Biotech, which focuses on cardiovascular and metabolic diseases, with several promising candidates in clinical trials [21][22] - Minwei Biotech's candidate drugs are leading in the domestic market, with significant advancements in clinical phases, particularly in obesity and type 2 diabetes treatments [22][23] Aesthetic Medicine - The aesthetic medicine segment is rapidly growing, with key products like the poly-L-lactic acid dermal filler and hyaluronic acid solutions receiving regulatory approval, indicating a strong market entry [24][25] - The company is actively expanding its non-insurance medical field, with high growth potential in the aesthetic sector [24]

Core Viewpoint - The approval of AcoArt Verbena® marks a significant breakthrough in the treatment of vertebral artery stenosis, ushering in a new era of "intervention without implantation" [2][4]. Group 1: "Intervention Without Implantation" Concept - The "intervention without implantation" concept aims to restore the health of blood vessels while avoiding the long-term issues associated with permanent implants, such as in-stent restenosis and chronic inflammation [4]. - This approach addresses the limitations of traditional metal stents, which can lead to complications over time [4]. Group 2: AcoArt Verbena® Overview - AcoArt Verbena® is the world's first drug-coated balloon (DCB) specifically designed for vertebral artery origin stenosis (VAOS), suitable for patients with ≥70% stenosis and ineffective drug therapy [9][10]. - The product utilizes advanced drug coating technology with magnesium stearate as a carrier for paclitaxel, enhancing drug stability and delivery efficiency [10]. Group 3: Clinical Trial Results - AcoArt Verbena® demonstrated a significant reduction in target lesion restenosis rates, with the trial group showing a 12-month restenosis rate of 13.04% compared to 37.31% in the control group, a decrease of 67% [16][13]. - The product avoids serious adverse events related to devices, mitigating risks associated with long-term metal stent implantation [16]. Group 4: Market Landscape and Competitive Position - The global peripheral DCB market was valued at 4.91 billion yuan in 2023, with a projected compound annual growth rate (CAGR) of 14.1%, reaching 12.28 billion yuan by 2030 [15]. - Xianruida holds an 86.9% market share in China's peripheral DCB market, indicating a strong competitive position [15]. - The collaboration with Boston Scientific is expected to enhance market penetration and revenue growth, with potential sales exceeding 1.2 billion yuan in the next three years [18][19]. Group 5: Company Background - Xianruida, founded in 2008 and listed on the Hong Kong Stock Exchange in 2021, focuses on innovative medical technologies in vascular intervention [20][21]. - The company has developed a diverse product pipeline, including several DCB products and other interventional devices, addressing unmet clinical needs across various medical fields [21].